|
|
| Drug Name: | HydrALAzine Hydrochloride |
| Manufacturer: | Barr Laboratories, Inc. |
| Other Info: | Manufactured by PLIVA Krakow Pharmaceutical Company S.A.,Krakow, Poland for PLIVA®, Inc., Pomona, NY 10970Distributed by Barr Laboratories, Inc. Pomona, NY 10970Revised APRIL 2007BR 398,327,328,397K21-032711001203 |
| Clinical Trials: | |
In a few patients hydrALAzine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis.
In such patients hydrALAzine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug.
Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later.
Long-term treatment with steroids may be necessary.
(See PRECAUTIONS, Laboratory Tests.)
NIH - Clinical Trials